Aug 2 (Reuters) - Antibe Therapeutics Inc
* Antibe Therapeutics receives approval to initiate phase 2 gastrointestinal endoscopy clinical trial
* Antibe Therapeutics Inc - it is anticipated that study will be completed in early 2018 for
* Antibe Therapeutics Inc - study is expected to begin immediately, and will be performed by Topstone Research, in Toronto Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.